TG Therapeutics (NASDAQ:TGTX) Shares Gap Down - Should You Sell?

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $43.44, but opened at $39.76. TG Therapeutics shares last traded at $36.46, with a volume of 3,322,561 shares trading hands.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Price Performance

The company has a market capitalization of $5.34 billion, a price-to-earnings ratio of -336.37 and a beta of 2.21. The business has a fifty day moving average price of $38.90 and a 200 day moving average price of $33.56. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. During the same quarter in the previous year, the business posted ($0.07) earnings per share. The company's quarterly revenue was up 90.4% on a year-over-year basis. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of TG Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. CWM LLC raised its stake in shares of TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after purchasing an additional 290 shares in the last quarter. Arizona State Retirement System grew its position in TG Therapeutics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares during the period. Finally, Summit Investment Advisors Inc. raised its position in TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after purchasing an additional 463 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.